Prosecution Insights
Last updated: April 19, 2026
Application No. 18/040,287

OLEFIN HYDROFORMYLATION PROCESSES USING HYDROCARBON SOLVENTS AND FLUORINATED SOLVENTS IN THE PRESENCE OF PHOSPHOLANE-PHOSPHITE LIGANDS

Final Rejection §DP
Filed
Feb 02, 2023
Examiner
BAHTA, MEDHANIT W
Art Unit
1692
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Eastman Chemical Company
OA Round
2 (Final)
80%
Grant Probability
Favorable
3-4
OA Rounds
2y 2m
To Grant
99%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allow Rate
613 granted / 763 resolved
+20.3% vs TC avg
Strong +29% interview lift
Without
With
+28.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 2m
Avg Prosecution
55 currently pending
Career history
818
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
35.8%
-4.2% vs TC avg
§102
18.2%
-21.8% vs TC avg
§112
30.3%
-9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 763 resolved cases

Office Action

§DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims The amendment filed on 01/23/2026 has been entered. to the claims has not been filed. Claims 1 has been amended and claim 13 has been canceled. Thus claims 1-12 and 14 are currently pending and are under examination. Withdrawn Rejection Claims 1-5 and 9-14 of the copending application 18/040,294 have been canceled. Thus, the statutory double patenting rejection has been withdrawn. Claim 1 has been amended to recite “the at least one olefin comprises propylene”. Applicant presents persuasive arguments with respect to US’751 in view of the international application WO2012/016147A2 (WO’147; cited in IDS 8/14/2023), by discussing that the claimed catalyst ligand I, even though considered homolog of the ligand of US’751, obtains a higher iso-selectivity of the aldehyde product than that of US’751. Moreover, WO’147, even though describes a generic formula of the ligand that includes -CH2-CH2- bridging the phospholate-phosphite, the reference exemplifies the same ligands as set forth in US’751, i.e. with -CH2- bridging. However, as presented in the examples and argued by the Applicant, the ligand with the -CH2- bridging does not provide a superior iso-selectivity when compared to the ligands as claimed. Thus, one of ordinary skill in the art would not have been motivated to select the ligand with -CH2-CH2-bridging from the generic formula of WO’147 to improve the iso-selectivity of the aldehyde product. Accordingly, the 103 rejection over Patent number US10,144,751 (US’751; cited in IDS 8/14/2023) in view of the international application WO2012/016147A2 (WO’147; cited in IDS 8/14/2023). Additionally, the 103 rejection over the international application WO2012/016147A2 (WO’147; cited in IDS 8/14/2023) has also been withdrawn as the reference fails to set forth propylene as the olefin. The nonstatutory double patenting rejection over the claims of U.S. Patent No. 10144751B1(‘751) in view of international application WO2012/016147A2 (WO’147; cited in IDS 8/14/2023) has also been withdrawn for the above reasons. Terminal Disclaimer The terminal disclaimer does not comply with 37 CFR 1.321 because: The filing date listed on the TD 02/04/2026 does not match the records. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-12 and 14 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-14 of copending Application No. 19455,139 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because they are drawn to a process for preparing at least one aldehyde under hydroformylation temperature and pressure conditions, comprising contacting at least one olefin with hydrogen and carbon monoxide in the presence of at least one solvent and a transition metal-based catalyst composition comprising a phospholane-phosphite ligand of formula I. Copending claim 1 fails to recite that the at least one olefin comprises propylene, but the deficiency is cured by the copending claim 13 that recites propylene comprised in the at least one olefin. Thus, a skilled artisan would arrive at the instant claimed invention by the combination of copending claims 1 and 13. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claims 1-12 and 14 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 19-28 of copending Application No. 18/040,294 in view of U.S. Patent No. 10144751B1(‘751). Claims 1-12 and 14 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 19-28 of copending Application No. 18/040,294 in view of international application WO2012/016147A2 (WO’147; cited in IDS 8/14/2023). The claims at issue are drawn to a process for preparing at least one aldehyde under hydroformylation temperature and pressure conditions, comprising contacting at least one olefin with hydrogen and carbon monoxide in the presence of at least one solvent and a transition metal-based catalyst composition comprising a phospholane-phosphite ligand of formula I. While the copending claim 1 suggests the use of the solvent in hydroformylation reaction, the claim fails to recite that the at least one solvent is one hydrocarbon solvent or fluorinated solvent as instantly claimed. The deficiency is however cured by US’751 or WO’147. In the same field of endeavor as the copending claims and instant invention, both US’751 and WO’147 teach a process for preparing at least one aldehyde under hydroformylation temperature and pressure conditions, comprising contacting at least one olefin with hydrogen and carbon monoxide in the presence of at least one solvent and a transition metal-based catalyst composition comprising a phospholane-phosphite ligand. The solvent used in the references is hydrocarbon or fluorinated solvent (US’751) and toluene (WO’147). As such, a skilled artisan would have been motivated to use the solvent of US’751 or WO’147 in the copending claim 1 and would have a reasonable expectation of success in arriving at the instantly claimed method. This is a provisional nonstatutory double patenting rejection. Allowable Subject Matter The subject matter of claims 1-12 and 14 is free of prior art references. The closest prior art references and their teachings have been set forth in the Office Action 07/23/2025. However, in view of the reasons set forth above, the instantly claimed invention is novel and unobvious. Conclusion Claims 1-12 and 14 are rejected and no claims are allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEDHANIT W BAHTA whose telephone number is (571)270-7658. The examiner can normally be reached Monday-Friday 8am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Scarlett Goon can be reached at 571-270-5241. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEDHANIT W BAHTA/ Primary Examiner, Art Unit 1692
Read full office action

Prosecution Timeline

Feb 02, 2023
Application Filed
Jul 21, 2025
Non-Final Rejection — §DP
Jan 23, 2026
Response Filed
Mar 11, 2026
Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600691
Process for Producing Mixed Alcohols from Purge Stream Containing Octene
2y 5m to grant Granted Apr 14, 2026
Patent 12590048
DINAPHTHYL ETHER COMPOUND AND LUBRICANT COMPOSITION CONTAINING SAME
2y 5m to grant Granted Mar 31, 2026
Patent 12577186
METHOD FOR PRODUCING ETHER
2y 5m to grant Granted Mar 17, 2026
Patent 12570592
HIGHER SECONDARY ALCOHOL ALKOXYLATE PRECURSOR, HIGHER SECONDARY ALCOHOL ALKOXYLATE ADDUCT AND HIGHER SECONDARY ALKYL ETHER SULFATE ESTER SALT, AND METHODS FOR PRODUCING THESE
2y 5m to grant Granted Mar 10, 2026
Patent 12565461
IMPROVED PROCESS FOR PREPARING BROMOCHLOROMETHANE
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
80%
Grant Probability
99%
With Interview (+28.6%)
2y 2m
Median Time to Grant
Moderate
PTA Risk
Based on 763 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month